Latest Breaking News On - Consumer brief summary - Page 1 : comparemela.com

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®

- AbbVie will present 15 abstracts, including three oral presentations, in Crohn s disease and ulcerative colitis reinforcing AbbVie s commitment to advancing.

United statesAnn gastroenterolGastroenterol hepatolAndrew anisfeldNational institute of diabetesInternational organization for the studyExchange commissionCrohn colitis foundationBoehringer ingelheimEuropean medicines agencyAmerican gastroenterological associationHealth economics cost of illnessSociety for surgery of the alimentary tractAbbvie incAmerican society for gastrointestinal endoscopyDrug administration

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

North chicagoUnited statesRoopal thakkarJ clin dermatolExchange commissionProgram to assess adverse eventsAbbvie incEczema areaSeverity indexWorst pruritus numerical rating scaleAtopic dermatitisImportant safetyMedication guideConsumer brief summaryFull prescribing informationAllergan aesthetics

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesKori wallaceProgram to assess adverse eventsExchange commissionAbbvie incArthritis foundationGiant cell arteritisImportant safetyMedication guideConsumer brief summaryMississippi riverAllergan aestheticsPrivate securities litigation reform actQuarterly reportsGiant cellAccessed april

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn s and Colitis Organisation (ECCO)

– A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie s commitment to produce a portfolio of products that aim to improve the lives of patients.

United statesRemo panaccioneAnn gastroenterolGastroenterol hepatolInternational medical affairsDrug administrationUniversity of calgaryNational institute of diabetesBoehringer ingelheimExchange commissionAbbvie incCrohn colitis foundationColitis organisationAbbvie ltdEuropean medicines agencyAbbvie deutschland gmbh co

AbbVie s SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn s Disease Meets All Primary and Secondary Endpoints

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn s.

Laurent peyrin birouletRoopal thakkarEuropean medicines agencyCrohn colitis foundation of americaAbbvie incUniversity hospital of nancyDrug administrationExchange commissionBoehringer ingelheimInfinity instituteAbbvie ltdDisease activity indexUnited european gastroenterologyAhead studyUniversity hospitalImportant safety information